Future therapies for hepatocellular carcinoma

European Journal of Gastroenterology and Hepatology

Volumn 17, Issue 5, 2005, Pages 515-521

  Sangro, Bruno ^a,b,c   Mazzollini, Guillermo ^a,b   Prieto, Jesus ^a,b  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c Clinica Universitaria   (Spain)

Author keywords

Anti angiogenesis; Gene therapy; Genetic immunotherapy; Genetic prodrug activation therapy; Hepatocellular carcinoma; Oncolytic virus; Targeted therapy

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTIMITOTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BEVACIZUMAB; CD137 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; CETUXIMAB; CYTOTOXIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ERLOTINIB; GEFITINIB; HERPESVIRUS VECTOR; INTERCELLULAR ADHESION MOLECULE 2; INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; LONAFARNIB; MELATONIN; MONOCLONAL ANTIBODY LM 609; ONCOLYTIC VIRUS; ONYX 015; PANITUMUMAB; PLASMINOGEN; PROTEIN P53; T LYMPHOCYTE ANTIBODY; THALIDOMIDE; THYMIDINE KINASE; TIPIFARNIB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR;

ADOPTIVE IMMUNOTHERAPY; ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; COLORECTAL CANCER; DENDRITIC CELL; DIGESTIVE SYSTEM CANCER; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; ERADICATION THERAPY; GASTROINTESTINAL CARCINOMA; GENE FUNCTION; GENE THERAPY; HUMAN; IMMUNOSTIMULATION; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER RESECTION; LYMPHOKINE ACTIVATED KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RECURRENT CANCER; REVIEW; SIDE EFFECT; TUMOR SUPPRESSOR GENE; VESICULAR STOMATITIS VIRUS; VIRAL GENE THERAPY;

ANGIOGENESIS INHIBITORS; CARCINOMA, HEPATOCELLULAR; FORECASTING; GENE THERAPY; HUMANS; IMMUNOTHERAPY; LIVER NEOPLASMS; PRODRUGS; VIRUS REPLICATION;

EID: 17844409103     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200505000-00007     Document Type: Review

References (77)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2:533-543.
2. Sangro B, Herraiz M, Martinez-Gonzalez MA, Bilbao I, Herrero I, Beloqui O, et al. Prognosis of hepatocellular carcinoma in relation to treatment: a multivariate analysis of 178 patients from a single European institution. Surgery 1998; 124:575-583.
3. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362:1907-1917.
4. Ito Y, Takeda T, Sakon M, Tsujimoto M, Higashiyama S, Noda K, et al. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer 2001; 84:1377-1383. This study attempts to elucidate the clinical significance of the erbB family in the development and behaviour of HCC.
5. Matsuo M, Sakurai H, Saiki I. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, shows antimetastatic activity using a hepatocellular carcinoma model. Mol Cancer Ther 2003; 2:557-561.
6. Sebti SM, Adjei AA. Farnesyltransferase inhibitors. Semin Oncol 2004; 31:28-39.
7. Hsu C, Chen CN, Chen LT, Wu CY, Yang PM, Lai MY, et al. Low-dose thalidomide treatment for advanced hepatocellular carcinoma. Oncology 2003; 65:242-249.
8. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Leiberman G, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21:60-65.
9. Patel SR, Jenkins J, Papadopolous N, Burgess MA, Plager C, Gutterman J, Benjamin RS. Pilot study of vitaxin - an angiogenesis inhibitor - in patients with advanced leiomyosarcomas. Cancer 2001; 92:1347-1348.
10. Lai CL, Lau JY, Wu PC, Ngan H, Chung HT, Mitchell SJ, et al. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology 1993; 17:389-394.
11. Llovet JM, Sala M, Castells L, Suarez Y, Vilana R, Bianchi L, et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000; 31:54-58.
12. Palmieri G, Montella L, Milo M, Fiore R, Biondi E, Bianco AR, Martignetti A. Ultra-low-dose interleukin-2 in unresectable hepatocellular carcinoma. Am J Clin Oncol 2002; 25:224-226. A small trial in which complete remissions were observed thus proving that immunotherapy may be of value against HCC.
13. Aldeghi R, Lissoni P, Barni S, Ardizzoia A, Tanchini G, Piperno A, et al. Low-dose interleukin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first-line therapy in locally advanced or metastatic hepatocellular carcinoma. Eur J Cancer 1994; 30A:167-170.
14. Kuhns MS, Epshteyn V, Sobel RA, Allison JP. Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates the size, reactivity, and function of a primed pool of CD4+ T cells. Proc Natl Acad Sci USA 2000; 97:12711-12716.
15. Murillo O, Arina A, Tirapu I, Alfaro C, Mazzolini G, Palencia B, et al. Potentiation of therapeutic immune responses against malignancies with monoclonal antibodies. Clin Cancer Res 2003; 9:5454-5464. A nice review of the potential role for immunostimulating monoclonal antibodies in the treatment of cancer.
16. Stift A, Friedl J, Dubsky P, Bachleitner-Hofmann T, Schueller G, Zontsich T, et al. Dendritic cell-based vaccination in solid cancer. J Clin Oncol 2003; 21:135-142.
17. Onishi S, Saibara T, Fujikawa M, Sakaeda H, Masuura Y, Matsunaga Y, Yamamoto Y. Adoptive immunotherapy with lymphokine-activated killer cells plus recombinant interleukin 2 in patients with unresectable hepatocellular carcinoma. Hepatology 1989; 10:349-353.
18. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000; 356:802-807.
19. Sangro B, Herraiz M, Prieto J. Gene therapy of neoplastic liver diseases. Int J Biochem Cell Biol 2003; 35:135-148. An interesting and extensive review on gene therapy of primary and secondary liver tumours.
20. Lotze MT, Kost TA. Viruses as gene delivery vectors: application to gene function, target validation, and assay development. Cancer Gene Ther 2002; 9:692-699.
21. Davis ME. Non-viral gene delivery systems. Curr Opin Biotechnol 2002; 13:128-131. Excellent review on the characteristics and potential applications of non-viral gene therapy vectors.
22. Sangro B, Qian C, Schmitz V, Prieto J. Gene therapy of hepatocellular carcinoma and gastrointestinal tumors. Ann NY Acad Sci 2002; 963:6-12.
23. Saleh M, Stacker SA, Wilks AF. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res 1996; 56:393-401.
24. Goldman CK, Kendall RL, Cabrera G, Soroceanu L, Heike Y, Gillespie GY, et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci USA 1998; 95:8795-8800.
25. Griscelli F, Li H, Bennaceur-Griscelli A, Soria J, Opolon P, Soria C, et al. Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc Natl Acad Sci USA 1998; 95:6367-6372.
26. Schmitz V, Wang L, Barajas M, Peng D, Prieto J, Qian C. A novel strategy for the generation of angiostatic kringle regions from a precursor derived from plasminogen. Gene Ther 2002; 9:1600-1606.
27. Ferreira CG, Tolis C, Giaccone G. p53 and chemosensitivity. Ann Oncol 1999; 10:1011-1021.
28. Xu GW, Sun ZT, Forrester K, Wang XW, Coursen J, Harris CC. Tissue-specific growth suppression and chemosensitivity promotion in human hepatocellular carcinoma cells by retroviral-mediated transfer of the wildtype p53 gene. Hepatology 1996; 24:1264-1268.
29. Anderson SC, Johnson DE, Harris MP, Engler H, Hancock W, Huang WM, et al. p53 gene therapy in a rat model of hepatocellular carcinoma: intra-arterial delivery of a recombinant adenovirus. Clin Cancer Res 1998; 4:1649-1659.
30. Choi JY, Park YM, Byun BH, Kim BS, Hong EG, Shin DY, et al. Adenovirus-mediated p53 tumor suppressor gene therapy against subcutaneous HuH7 hepatoma cell line nodule of nude mice. J Korean Med Sci 1999; 14:271-276.
31. Habib NA, Mitry RR, Sadri R. p53 and gene therapy for hepatocellular carcinoma. Adv Exp Med Biol 1998; 451:499-504. Conflicting results from the first clinical trial in which p53 based gene therapy was given to patients with HCC.
32. Fillat C, Carrio M, Cascante A, Sangro B. Suicide gene therapy mediated by the herpes simplex virus thymidine kinase gene/ganciclovir system: fifteen years of application. Curr Gene Ther 2003; 3:13-26. Excellent review on this prodrug activating gene therapy strategy, stressing their implications and limitations.
33. Herraiz M, Beraza N, Solano A, Sangro B, Montoya J, Qian C, et al. Liver failure caused by herpes simplex virus thymidine kinase plus ganciclovir therapy is associated with mitochondrial dysfunction and mitochondrial DNA depletion. Hum Gene Ther 2003; 14:463-472. First paper to describe the effect of the tk strategy on mitochondrial DNA synthesis, a finding that helps to explain the damage to non-dividing cells.
34. Mesnil M, Yamasaki H. Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication. Cancer Res 2000; 60:3989-3999.
35. Kianmanesh AR, Perrin H, Panis Y, Fabre M, Nagy HJ, Houssin D, Klatzmann D, et al. A 'distant' bystander effect of suicide gene therapy: regression of nontransduced tumors together with a distant transduced tumor. Hum Gene Ther 1997; 8:1807-1814.
36. Bilbao R, Gerolami R, Bralet MP, Qian C, Tran PL, Tennant B, et al. Transduction efficacy, antitumoral effect, and toxicity of adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir therapy of hepatocellular carcinoma: the woodchuck animal model. Cancer Gene Ther 2000; 7: 657-662.
37. Qian C, Bilbao R, Bruna O, Prieto J. Induction of sensitivity to ganciclovir in human hepatocellular carcinoma cells by adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase. Hepatology 1995; 22:118-123.
38. Qian C, Idoate M, Bilbao R, Sangro B, Bruna O, Vazguez J, Prieto J, et al. Gene transfer and therapy with adenoviral vector in rats with diethylnitrosamine-induced hepatocellular carcinoma. Hum Gene Ther 1997; 8:349-358.
39. Bustos M, Sangro B, Alzuguren P, Gil AG, Ruiz J, Beraza N, et al. Liver damage using suicide genes. A model for oval cell activation. Am J Pathol 2000; 157:549-559.
40. van der Eb MM, Cramer SJ, Vergouwe Y, Schagen FH, van Krieken JH, van der Eb AJ, et al. Severe hepatic dysfunction after adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene and ganciclovir administration. Gene Ther 1998; 5:451-458.
41. Qiao J, Doubrovin M, Sauter BV, Huang Y, Quo ZS, Balatoni J, et al. Tumor-specific transcriptional targeting of suicide gene therapy. Gene Ther 2002; 9:168-175.
42. Sung MW, Yeh HC, Thung SN, Schwartz ME, Mandeli JP, Chen SH, Woo SL. Intratumoral adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: results of a phase I clinical trial. Mol Ther 2001; 4:182-191. The first clinical trial reporting on percutaneous injection into liver tumours of an adenovirus encoding thymidine kinase followed by systemic ganciclovir. Therapy was proven to be safe but ineffective.
43. Kuriyama S, Mitoro A, Yamazaki M, Tsujinoue H, Nakatani T, Akahane T, et al. Comparison of gene therapy with the herpes simplex virus thymidine kinase gene and the bacterial cytosine deaminase gene for the treatment of hepatocellular carcinoma. Scand J Gastroenterol 1999; 34:1033-1041.
44. Mohr L, Shankara S, Yoon SK, Krohne TU, Geissler M, Roberts B, et al. Gene therapy of hepatocellular carcinoma in vitro and in vivo in nude mice by adenoviral transfer of the Escherichia coli purine nucleoside phosphorylase gene. Hepatology 2000; 31:606-614.
45. Hawkins LK, Lemoine NR, Kirn D. Oncolytic biotherapy: a novel therapeutic platform. Lancet Oncol 2002; 3:17-26.
46. Stanziale SF, Fong Y. Novel approaches to cancer therapy using oncolytic viruses. Curr Mol Med 2003; 3:61-71.
47. Kirn D. Oncolytic virotherapy for cancer with the adenovirus dI1520 (Onyx-015): results of phase I and II trials. Expert Opin Biol Ther 2001; 1:525-538. Extensive description of the clinical development of an oncolytic adenovirus for the treatment of cancer. In-vivo replication was suggested and a possible therapeutic effect was observed when given in combination with chemotherapy.
48. Habib NA, Sarraf CE, Mitry RR, Havlik R, Nicholls J, Kelly M, et al. E1B-deleted adenovirus (dI1520) gene therapy for patients with primary and secondary liver tumors. Hum Gene Ther 2001; 12:219-226. Early trial evaluating the administration of an oncolytic adenovirus to patients with liver tumours by different routes, either alone or in combination with chemotherapy.
49. Habib N, Salama H, Abd El Latif Abu Median A, Isac Anis I, Abd Al Aziz RA, Sarraf C, et al. Clinical trial of E1B-deleted adenovirus (dI1520) gene therapy for hepatocellular carcinoma. Cancer Gene Ther 2002; 9:254-259. A randomized trial that evaluates intratumoral injection of an oncolytic adenovirus to five patients with HCC in comparison with five patients treated by percutaneous ethanol injection. Significant activity was not found.
50. Reid T, Galanis E, Abbruzzese J, Sze D, Wein LM, Andrews J, et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dI1520): phase II viral, immunologic, and clinical endpoints. Cancer Res 2002; 62:6070-6079.
51. Li Y, Yu DC, Chen Y, Amin P, Zhang H, Nguyen N, Henderson DR. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Cancer Res 2001; 61:6428-6436.
52. Irving J, Wang Z, Powell S, O'Sullivan C, Mok M, Murphy B, et al. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity. Cancer Gene Ther 2004; 11:174-185.
53. Jakubczak JL, Ryan P, Gorziglia M, Clarke L, Hawkins LK, Hay C, et al. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy. Cancer Res 2003; 63:1490-1499.
54. Pawlik TM, Nakamura H, Yoon SS, Mullen JT, Chandrasekhar S, Choicca EA, Tanabe KK. Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus. Cancer Res 2000; 60:2790-2795.
55. Ebert O, Shinozaki K, Huang TG, Savontaus MJ, Garcia-Sastre A, Woo SL. Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats. Cancer Res 2003; 63:3605-3611.
56. Bristol JA, Zhu M, Ji H, Mina M, Xie Y, Clarke L, et al. In vitro and in vivo activities of an oncolytic adenoviral vector designed to express GM-CSF. Mol Ther 2003; 7:755-764.
57. Jarnagin WR, Zager JS, Klimstra D, Delman KA, Malhotra S, Ebright M, et al. Neoadjuvant treatment of hepatic malignancy: an oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence after resection. Cancer Gene Ther 2003; 10:215-223.
58. Sasaki E, Osawa R, Nishitani Y, Whiley RA. Development of a diagnostic PCR assay targeting the Mn-dependent superoxide dismutase gene (sodA) for identification of Streptococcus gallolyticus. J Clin Microbiol 2004; 42:1360-1362.
59. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004; 4:11-22.
60. Reilly RT, Machiels JP, Emens LA, Jaffee EM. Cytokine gene-modified cell-based cancer vaccines. Methods Mol Med 2002; 69:233-257.
61. Barajas M, Mazzolini G, Genove G, Bilbao R, Narvaiza I, Schmitz V, et al. Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12. Hepatology 2001; 33:52-61. Preclinical model setting the proof-of-concept for interleukin 12-based gene therapy of HCC.
62. Sangro B, Mazzolini G, Ruiz J, Herraiz M, Quiroga J, Herrero I, et al. Phase I trial of intratumoral injection of an adenovirus encoding interleukin 12 for advanced digestive tumors. J Clin Oncol 2004; 22:1389-1397. The first clinical trial in which patients with gastrointestinal tumors were submitted to genetic immunotherapy using an adenovirus encoding interleukin 12. Therapy was safe and biological as well as therapeutic activity were observed, particularly among patients with HCC.
63. Narvaiza I, Mazzolini G, Barajas M, Duarte M, Zaratiegui M, Qian C, et al. Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy. J Immunol 2000; 164:3112-3122.
64. Mazzolini G, Narvaiza I, Martinez-Cruz LA, Anna A, Barajas M, Galofre JC, et al. Pancreatic cancer escape variants that evade immunogene therapy through loss of sensitivity to IFNgamma-induced apoptosis. Gene Ther 2003; 10:1067-1078.
65. Putzer BM, Stiewe T, Rodicker F, Schildgen O, Ruhm S, Dirsch O, et al. Large nontransplanted hepatocellular carcinoma in woodchucks: treatment with adenovirus-mediated delivery of interleukin 12/B7.1 genes. J Natl Cancer Inst 2001; 93:472-479. An interesting study that shows a strong antitumoral effect of intratumoral injection of an adenoviral vector encoding both interleukin-12 and B7.1 in a quite hard model of HCC.
66. Drozdzik M, Qian C, Xie X, Peng D, Bilbao R, Mazzolini G, Prieto J. Combined gene therapy with suicide gene and interleukin-12 is more efficient than therapy with one gene alone in a murine model of hepatocellular carcinoma. J Hepatol 2000; 32:279-286.
67. Mazzolini G, Qian C, Narvaiza I, Barajas M, Borras-Cuesta F, Zie X, et al. Adenoviral gene transfer of interleukin 12 into tumors synergizes with adoptive T cell therapy both at the induction and effector level. Hum Gene Ther 2000; 11:113-125.
68. Mazzolini G, Narvaiza I, Perez-Diez A, Rodriguez-Calvillo M, Qian C, Sangro B, et al. Genetic heterogeneity in the toxicity to systemic adenoviral gene transfer of interleukin-12. Gene Ther 2001; 8:259-267.
69. Banchereau J, Paczesny S, Blanco P, Bennett L, Pascual V, Fay J, Palucka AK. Dendritic cells: controllers of the immune system and a new promise for immunotherapy. Ann NY Acad Sci 2003; 987:180-187.
70. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Ann Rev Immunol 1998; 16:111-135.
71. Schmitz V, Barajas M, Wang L, Peng D, Duarte M, Prieto J, Qian C. Adenovirus-mediated CD40 ligand gene therapy in a rat model of orthotopic hepatocellular carcinoma. Hepatology 2001; 34:72-81.
72. Tirapu I, Rodriguez-Calvillo M, Qian C, Duarte M, Smerdou C, Palencia B, et al. Cytokine gene transfer into dendritic cells for cancer treatment. Curr Gene Ther 2002; 2:79-89. A review of what gene therapy can add to cell immunotherapy based on the use of dendritic cells.
73. Vollmer CM Jr, Eilber FC, Butterfield LH, Ribas A, Dissette VB, Koh A, et al. Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma. Cancer Res 1999; 59:3064-3067.
74. Melero I, Duarte M, Ruiz J, Sangro B, Galofre J, Mazzolini G, et al. Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas. Gene Ther 1999; 6:1779-1784.
75. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2002; 2:683-693. A comprehensive review of what positron emission tomography imaging techniques can offer to in-vivo tracing of gene expression and, accordingly, to the clinical development of gene therapy.
76. Sangro B, Qian C, Ruiz J, Prieto J. Tracing transgene expression in cancer gene therapy: a requirement for rational progress in the field. Mol Imaging Biol 2002; 4:27-33.
77. Wang L, Hernandez-Alcoceba R, Shankar V, Zabala M, Kochanek S, Sangro B, et al. Prolonged and inducible transgene expression in the liver using gutless adenovirus: a potential therapy for liver cancer. Gastroenterology 2004; 126:278-289.